Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado-Denver, Aurora, CO 80045, USA.
J Pharmacol Exp Ther. 2011 Mar;336(3):874-80. doi: 10.1124/jpet.110.176438. Epub 2010 Dec 14.
Previous work demonstrated that NAD(P)H:quinone oxidoreductase 1 (NQO1) metabolized the heat shock protein 90 (Hsp90) inhibitor 17-(allylamino)-17-demethoxygeldanamycin (17AAG) to the corresponding hydroquinone (17AAGH₂). The formation of 17AAGH₂ by NQO1 results in a molecule that binds with greater affinity to Hsp90 compared with the parent quinone. 17AAG induced substantial growth inhibition in human pancreatic cancer cell lines expressing NQO1. Growth inhibition induced by 17AAG could be reduced by pretreatment with 5-methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]-indole-4,7-dione (ES936), a mechanism-based inhibitor of NQO1. After treatment with 17AAG, biomarkers of Hsp90 inhibition, including markers of cell-cycle arrest, were more pronounced in NQO1-expressing cells compared with NQO1-null cells. The intracellular concentrations of 17AAG and 17AAGH₂ were measured in human pancreatic cancer cells, and it was observed that larger amounts of 17AAG and 17AAGH₂ could be detected in cells with catalytically active NQO1 compared with cells lacking NQO1 activity or cells pretreated with ES936. These data demonstrate that, in addition to generating an inhibitor with greater affinity for Hsp90 (17AAGH₂), reduction of 17AAG to 17AAGH₂ by NQO1 leads to substantially greater intracellular concentrations of 17AAG and 17AAGH₂. In addition, oxidation of 17AAGH₂ could be prevented by superoxide dismutase (SOD), demonstrating that 17AAGH₂ was sensitive to oxidation by superoxide. Stable transfection of manganese-dependent SOD into MiaPaCa-2 cells resulted in a significantly greater intracellular concentration of 17AAGH₂ with a corresponding increase in growth inhibitory activity. These data confirm the role of NQO1 in sensitivity to 17AAG and demonstrate that SOD functions in conjunction with NQO1 to maintain intracellular levels of 17AAGH₂, the active Hsp90 inhibitor derived from 17AAG.
先前的工作表明,NAD(P)H:醌氧化还原酶 1(NQO1)将热休克蛋白 90(Hsp90)抑制剂 17-(烯丙氨基)-17-去甲氧基格尔德霉素(17AAG)代谢为相应的氢醌(17AAGH₂)。NQO1 形成的 17AAGH₂与母醌相比,与 Hsp90 的结合亲和力更强。在表达 NQO1 的人胰腺癌细胞系中,17AAG 诱导显著的生长抑制。用 5-甲氧基-1,2-二甲基-3-[(4-硝基苯氧基)甲基]-吲哚-4,7-二酮(ES936)预处理可降低 17AAG 诱导的生长抑制,ES936 是 NQO1 的一种基于机制的抑制剂。用 17AAG 处理后,与 NQO1 缺失细胞相比,在表达 NQO1 的细胞中,Hsp90 抑制的生物标志物,包括细胞周期停滞的标志物,更为明显。在人胰腺癌细胞中测量了 17AAG 和 17AAGH₂的细胞内浓度,并且观察到与缺乏 NQO1 活性的细胞或用 ES936 预处理的细胞相比,具有催化活性的 NQO1 的细胞中可以检测到更多量的 17AAG 和 17AAGH₂。这些数据表明,除了生成与 Hsp90 具有更高亲和力的抑制剂(17AAGH₂)之外,NQO1 将 17AAG 还原为 17AAGH₂ 会导致 17AAG 和 17AAGH₂ 的细胞内浓度显著增加。此外,超氧化物歧化酶(SOD)可以阻止 17AAGH₂的氧化,表明 17AAGH₂易受超氧化物的氧化。将锰依赖性 SOD 稳定转染到 MiaPaCa-2 细胞中,导致 17AAGH₂的细胞内浓度显著增加,相应地生长抑制活性增加。这些数据证实了 NQO1 在对 17AAG 的敏感性中的作用,并表明 SOD 与 NQO1 一起发挥作用以维持 17AAGH₂的细胞内水平,17AAGH₂是源自 17AAG 的活性 Hsp90 抑制剂。